As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

D imaging and organoid models are revolutionizing dementia research, offering deeper insights into disease mechanisms and ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

Nov. 19, 2024 — Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new ... Earlier Diabetes Diagnosis Linked to Dementia Risk Nov. 19, 2024 ...

Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

Individuals who suffer head trauma from sports, accidents, or other causes often go on to develop neurodegenerative diseases ...

The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...

How Dementia Affects the ... of Huntington's disease (HD), according to a new ... 'Alzheimer's in Dish' Model Shows Promise for Accelerating Drug Discovery Nov. 27, 2024 — A decade ago ...